Assessing symptom distress in cancer patients

Cleeland, Charles S.; Mendoza, Tito R.; Wang, Xin Shelley; Chou, Chyi; Harle, Margaret T.; Morrissey, Marilyn; Engstrom, Martha C.

doi:10.1002/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v

Cited by 1,175 publications

(937 citation statements)

References 28 publications

Supporting

Mentioning

902

Contrasting

Unclassified

Order By: Relevance

“…Te MD Anderson Symptom Inventory (MDASI) 19 was used to measure key symptoms daily for the entire study period. Te use of the MDASI in this study was to determine if there were any toxicities related to the antiemetic regimens.…”

Section: Study Visits and Assessment Proceduresmentioning

confidence: 99%

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting

Navari¹,

Nagy²,

Le‐Rademacher³

et al. 2016

J Community Support Oncol

View full text Add to dashboard Cite

Section: Study Visits and Assessment Proceduresmentioning

confidence: 99%

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting

Navari¹,

Nagy²,

Le‐Rademacher³

et al. 2016

J Community Support Oncol

View full text Add to dashboard Cite

“…Each symptom is rated at its worst in the 24 hours prior to completion. 24 Symptoms included on the instrument include those common in PBT patients and those associated with cancer therapies. The average time to complete the MDASI-BT is 5 minutes.…”

Section: Instrumentsmentioning

confidence: 99%

Congruence of primary brain tumor patient and caregiver symptom report

Armstrong

Wefel

Gning

et al. 2012

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Evaluating the severity of symptoms in patients with primary brain tumors (PBTs) is important in clinical care and research but may be difficult due to patient neurocognitive (NC) impairment. This study was conducted to evaluate the congruence of symptom reporting in patient and caregiver dyads, examining potential impact of NC impairment and Karnofsky performance status (KPS). METHODS: PBT patients undergoing NC testing and their caregivers were included in this study. These dyads (paired patient and caregiver group) completed the MD Anderson Symptom Inventory-Brain Tumor Module prior to testing, and impairment was categorized based on NC test scores. Concordance and equivalency was then assessed using Bland-Altman analysis and 2 onesided techniques. RESULTS: A total of 115 dyads participated. Median patient and caregiver age was 49 and 51 years, respectively, and 63% of patients were male (73% female caregivers). Most patients had a good KPS (!90, 66%) but were classified as NC impaired (58%). Caregiver's report of patient symptoms are congruent to the self-report of the patient. Equivalency between patient and caregiver report were found using prespecified confidence intervals. KPS group (good, !90; poor, 80) comparisons of equivalency indicated no significant differences in symptoms and interference reporting between dyads (good ¼ 0.49, P >.05; and poor ¼ 0.3, P >.05) overall, but there was a tendency for higher report by caregivers if the patients had a poor KPS. CONCLUSIONS: Caregivers of PBT patients have similar assessments of symptom severity (highly congruent) with patient self-report regardless of NC function or KPS. These findings suggest that caregivers may serve as proxy report of symptoms for primary brain tumor patients.

show abstract

“…These symptoms greatly influence a patient's functional status and may even cause the patient to change or abandon an active treatment plan. [1][2][3] Oncology clinicians and researchers, therefore, have a critical need for a standardized tool to assess multiple symptoms. Although a multiple-symptom assessment tool may overlap with other measures (such as single-symptom pain and fatigue assessment tools and certain symptom subscales in health- related quality of life [QOL] measures), multisymptom scales nonetheless provide a rapid assessment method for monitoring and evaluating the effectiveness of treatments for cancer and its symptoms and for documenting treatment side effects observed in research and in clinical practice.…”

mentioning

confidence: 99%

Chinese version of the M. D. Anderson Symptom Inventory

Wang

Guo

et al. 2004

Cancer

Self Cite

166

View full text Add to dashboard Cite

BACKGROUNDSymptom management is an essential component of cancer treatment for patients of every culture and nationality. Symptom assessment depends on subjective reporting, mandating linguistically equivalent versions of symptom assessment scales. Because disease‐related and treatment‐related symptoms most often occur in clusters, there is a global need for a standardized multiple‐symptom assessment tool.METHODSThe authors sought to validate the Chinese version of the M. D. Anderson Symptom Inventory (MDASI‐C) by enrolling patients who had received various diagnoses of and different types of treatment for cancer (n = 249) in a cross‐sectional symptom study conducted at an urban cancer center in China.RESULTSFactor analysis identified 2 underlying constructs, general symptoms and gastrointestinal symptoms, which had Cronbach alpha coefficients of 0.86 and 0.84, respectively. These results were consistent with English‐ and Japanese‐language MDASI validation studies. Known‐group validity was supported by the MDASI‐C's ability to detect significant differences in symptom and interference levels according to Eastern Cooperative Oncology Group performance status (ECOG PS; P < 0.001) and chemotherapy status (P < 0.05). Fifty‐five percent of the study cohort had ≥ 1 symptom that was considered severe (score ≥ 7 on a 0–10 scale). ECOG PS was strongly associated with symptom burden (total interference score: R2 = 0.26; P < 0.001). Fatigue, sadness, drowsiness, and lack of appetite accounted for most of the variability in the total interference score (R2 = 0.49; P < 0.05).CONCLUSIONSThe authors demonstrated that the MDASI‐C is a valid, reliable, and concise tool for measuring symptom severity and interference with functioning in Chinese cancer patients. Cancer 2004. © 2004 American Cancer Society.

show abstract

Assessing symptom distress in cancer patients

Cited by 1,175 publications

References 28 publications

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting

Congruence of primary brain tumor patient and caregiver symptom report

Chinese version of the M. D. Anderson Symptom Inventory

Contact Info

Product

Resources

About